Neurodegenerative proteins found in gut biopsies, years before the brain declared itself

Design

Retrospective histopathological analysis of archival biopsies with 13-15 years of clinical follow-up

Population

196 individuals who underwent gastrointestinal biopsy for unexplained GI symptoms

Primary outcome

Later diagnosis of neurodegenerative disease, and survival, by presence of misfolded TDP-43, tau or alpha-synuclein in gut tissue

Effect

Protein misfolding enteropathy in 60%; sensitivity above 80% for non-Alzheimer's dementia or alpha-synucleinopathy with low specificity; two or more markers associated with dose-dependent reduction in survival; changes present a mean of 6.9 years before neurological symptoms

Misfolded TDP-43, tau and alpha-synuclein define the major neurodegenerative diseases, and the enteric nervous system has long been suspected as an early site. This study went looking in the most ordinary place available: archival gastrointestinal biopsies taken from 196 people investigated for unexplained GI symptoms, with 13 to 15 years of subsequent follow-up, restained with sensitive histopathological methods.

Protein misfolding enteropathy was present in 60%. Those with it were significantly more likely to go on to develop non-Alzheimer's dementia or an alpha-synucleinopathy, with sensitivity above 80% — but the authors immediately qualify this with low specificity, which in a 60% prevalence finding is the number that governs its usefulness. Two or more proteinopathy markers went with progressively shorter survival, independently of other factors. The pathological changes preceded neurological symptoms by a mean of 6.9 years.

Nothing about this is ready to be offered to a patient. A test with high sensitivity and low specificity applied to people with unexplained gut symptoms would label a great many people who will never develop neurodegeneration, with no treatment to offer them. Its real use is the one the authors name: a scalable tissue platform for prevention trials, which need to enrol people years before symptoms and currently have almost no way of finding them.

• Do not request or report proteinopathy staining on clinical GI biopsies
• Do not raise this with patients who have unexplained GI symptoms; there is no action to offer
• The prognostic signal is real but the specificity makes individual prediction unreliable
• The population is people with unexplained GI symptoms, not the general population
• Watch for this as an enrolment tool in neurodegeneration prevention trials

Why it matters

It suggests the tissue needed to identify people before neurodegeneration declares itself is already sitting in pathology archives.

Don't overread it

High sensitivity with low specificity in a population where 60% test positive does not make this a predictive test for an individual.

The statistics, in plain English

Sensitivity above 80% with low specificity means the test rarely misses someone who will develop disease but flags many who will not. When the finding is present in 60% of everyone tested, most positives will be false: a positive result would change an individual's probability far less than the headline sensitivity suggests. The 6.9-year lead time is a mean in a cohort selected for having had a biopsy, not an interval you could quote to a person.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.